Pfizer and Keas Partner to Help Consumers Take a More Active Role in Their Health and Wellness

PfizerPfizer and Keas announced today they have entered into an alliance to collaborate on the Keas platform to enable Health and Wellness experts to author, sell and distribute personalized online Care Plans directly to patients. Pfizer and Keas will collaborate to develop care plans and related capabilities that seek to provide consumers, patients and their providers an intuitive, engaging, easy-to-use, and low-cost way to manage their health & wellness, prevention and care delivery.

An asset for both consumers and their physicians, Keas allows users to understand and take charge of their health information by using Care Plans that meet their personal health needs and help extend the reach of their own physicians and health care providers. The Care Plans are authored by leaders in the healthcare industry including doctors, pharmacists, and nutritionists. Among the health experts who have published Care Plans on Keas include Dr. Greene Pediatrics, DiabetesMine, HealthWise, and CVS MinuteClinic.

"Our partnership with Keas demonstrates Pfizer's commitment to invest in innovative and game changing solutions that empower patients and physicians to further engage in the patient's health," said Kristin Peck, SVP of Worldwide Strategy & Innovation. "This is a further testimony of Pfizer's commitment to remain the partner of choice for entrepreneurs and innovators. It is about harnessing the power of the best innovators across the world through new partnerships and novel ecosystems to create a healthier world."

Keas offers a fun, personalized "dashboard" to users giving them the opportunity to keep track of their own health goals and empower them to make decisions about self-care as well as medical care. Keas Founder and CEO Adam Bosworth explains, "Keas helps people take charge of their health, giving them the tools and knowledge required to live a healthy life and tackle such challenges as weight loss, smoking cessation, diabetes prevention or control, heart disease, pediatric issues and even reminders for taking prescriptions or getting lab work done."

"The Pfizer relationship with Keas enables us to partner with health care professionals to extend care management outside the office," said Olivier Brandicourt, President and General Manager of Pfizer's Primary Care Business Unit. "By combining the recommendation of an individual's physician with a personalized, expert-developed Care Plan to support day-to-day health decisions, we believe patients will potentially experience improved health outcomes."

Patients using the interactive platform also will be able to share their Care Plan with a designated provider, following the progress of the patient with the Plan to provide collaborative care. Patients can enroll directly into Care plans or by recommendation of their physician.

About Keas
Keas (www.keas.com) is an interactive service that enables the best medical minds in healthcare to provide individuals with ongoing advice and interpretation about their unique health data - such as lab results and current conditions - and help them take action to achieve their health goals.

Pfizer Inc: Working together for a healthier world™
At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people and animals. Our diversified global health care portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and many of the world's best-known consumer products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as the world's leading biopharmaceutical company, we also collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. To learn more about our commitments, please visit us at www.pfizer.com.

Most Popular Now

In wine, there's health: Low levels of alcohol goo…

While a couple of glasses of wine can help clear the mind after a busy day, new research shows that it may actually help clean the mind as well. The new study, which appe...

Sanofi to acquire Ablynx for €3.9 Billion

Sanofi and Ablynx, a biopharmaceutical company engaged in the discovery and development of Nanobodies®, entered into a definitive agreement under which Sanofi will offer ...

Repurposed drug found to be effective against Zika…

In both cell cultures and mouse models, a drug used to treat Hepatitis C effectively protected and rescued neural cells infected by the Zika virus - and blocked transmiss...

Interim publications of randomized trials make new…

Early results from randomized trials are sometimes published before the trial is completed. The results of such interim publications may generate a great deal of interest...

More stroke patients may receive crucial treatment…

More patients could be eligible for critical treatments to remove or dissolve blood clots that cause strokes, according to a new treatment guideline issued by the America...

Drug trial protocol redactions by industry sponsor…

New research published by the Journal of the Royal Society of Medicine exposes the extent of redactions in protocols for industry-sponsored randomised drug trials. Trial ...

Advanced Accelerator Applications receives FDA ap…

Novartis AG (NYSE: NVS) announced that Advanced Accelerator Applications, a subsidiary of Novartis Groupe S.A., has received US Food and Drug Administration (FDA) approva...

Blood vessel-on-a-chips show anti-cancer drug effe…

Researchers at the Institute of Industrial Science (IIS), the University of Tokyo, CNRS and INSERM, report a new organ-on-a-chip technology for the study of blood vessel ...

Guidelines extended to improve the use of feedback…

Researchers have recommended changes to international guidelines used in the development of clinical trials in an effort to gain information about the impact of the treat...

Roche reports good results in 2017

In 2017, Group sales rose 5% to CHF 53.3 billion. Core operating profit grew 3% and Core EPS increased 5%, reflecting the good underlying business performance. On an IFRS...

Brilinta significantly reduces CV events and coron…

AstraZeneca today announced results from a new sub-analysis of the Phase III PEGASUS-TIMI 54 trial, demonstrating a risk reduction of 19% in MACE (the composite of CV dea...

FDA approves new treatment for certain digestive t…

The U.S. Food and Drug Administration today approved Lutathera (lutetium Lu 177 dotatate) for the treatment of a type of cancer that affects the pancreas or gastrointesti...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]